Exelixis (EXEL) Non Operating Income (2010 - 2026)
Exelixis (EXEL) recorded quarterly Non Operating Income of $219000.0 in Q2 2026, up 376.09% quarter-over-quarter from $46000.0 in Q1 2026, and up 189.39% on a YoY basis from $75677.0 in Q2 2025.
Exelixis (EXEL) Non Operating Income (2010 - 2026) Analysis & Trends
Exelixis' Non Operating Income history runs 17 years deep, the most recent figure standing at $219000.0 for Q2 2026.
- In Q2 2026, Non Operating Income rose 189.39% year-over-year to $219000.0; the TTM figure through Apr 2026 stood at $266000.0 (up 192.04% YoY), while the FY2026 annual figure was -$198000.0, down 48.87% from the prior year.
- Non Operating Income was $219000.0 for Q2 2026 at Exelixis, up from $46000.0 in the prior quarter.
- In the past five years, Non Operating Income ranged from a high of $289000.0 in Q3 2023 to a low of -$337000.0 in Q4 2022.
- Historically, Non Operating Income has averaged -$12705.9 across 5 years, with a median of -$29000.0 in 2024.
- The sharpest annual moves came in 2023 and 2024: Non Operating Income soared 518.84% in 2023, then sank 5640.0% in 2024.
- A 5-year view of Non Operating Income shows it stood at -$337000.0 in 2022, then surged by 59.35% to -$137000.0 in 2023, then jumped by 78.83% to -$29000.0 in 2024, then slumped by 68.97% to -$49000.0 in 2025, then soared by 546.94% to $219000.0 in 2026.
- The last three Non Operating Income figures came in at $219000.0 (Q2 2026), $46000.0 (Q1 2026), and -$49000.0 (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | 5.75 Mn |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | - |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | 444,000.00 |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | - |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | 9.35 Mn |
| 10 | Exelixis | 13.71 Bn | 12.93 Bn | 590.86 Mn | 219,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 219,000.00 |
| Jan 2, 2026 | 46,000.00 |
| Oct 3, 2025 | -49,000.00 |
| Jul 4, 2025 | 50,000.00 |
| Apr 4, 2025 | -245,000.00 |
| Jan 3, 2025 | 272,000.00 |
| Sep 27, 2024 | -29,000.00 |
| Jun 28, 2024 | -287,000.00 |
| Mar 29, 2024 | -89,000.00 |
| Dec 29, 2023 | -137,000.00 |
| Sep 29, 2023 | 289,000.00 |
| Jun 30, 2023 | -5,000.00 |
| Mar 31, 2023 | -54,000.00 |
| Dec 30, 2022 | -337,000.00 |
| Sep 30, 2022 | -69,000.00 |
| Jul 1, 2022 | 45,000.00 |
| Apr 1, 2022 | 164,000.00 |
| Dec 31, 2021 | -64,000.00 |
| Oct 1, 2021 | -19,000.00 |
| Jul 2, 2021 | -11,000.00 |